Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
Recommended Citation
Cheng JWM, Colucci V, Kalus JS, and Spinler SA. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease. Ann Pharmacother 2020.
Document Type
Article
Publication Date
6-13-2020
Publication Title
The Annals of pharmacotherapy
Abstract
Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicated early signals in benefiting heart failure (HF) patients and those with chronic kidney diseases. This article reviews recent and future clinical studies that focus on evaluation of the use of SGLT2 inhibitors in HF management and renal protection.
Medical Subject Headings
Diabetes Mellitus; Type 2/complications/drug therapy/metabolism; Heart Failure/complications/drug therapy/metabolism; Humans; Renal Insufficiency; Chronic/complications/drug therapy/metabolism; Sodium-Glucose Transporter 2/metabolism; Sodium-Glucose Transporter 2 Inhibitors/administration & dosage/adverse; effects/therapeutic use; chronic kidney disease; diabetes; heart failure; sodium-glucose cotransporter 2 inhibitors
PubMed ID
32536199
ePublication
ePub ahead of print
Volume
55
Issue
2
First Page
252
Last Page
260
